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Abstract
Introduction: HLA-B27 is considered as one of the causes of heart conductive 
disorders. We studied the frequency of HLA-B27 among Iranian patients who had 
undergone permanent pacemaker implantation.
Methods: This descriptive and analytical study was performed among patients 
who underwent permanent pacemaker implantation. The questionnaire contains 
demographic data, underling diseases, and history of heart disease or heart surgery.
The type of conductive heart disorder was mentioned there, too. We determined the 
regurgitation of aorta valve and its severity. Finally, HLA-B27 was accessed.All the data 
was entered in SPSS software and analyzed.
Results: From a total of 103 patients entered in this study, only 6 (5.8%) were HLA-
B27-positive. The disturbance of conductive heart disorders based on the HLA-B27 
positive or negative patients was not statistically different. Patients with HLA-B27 
mostly had regurgitation of the aorta valve.
Conclusions: We concluded that the frequency of positive HLA-B27 genotype in 
patients with permanent pacemakers did not have any significant difference with the 
ones with negative HLA-B27 genotype. However; this genotype was associated with 
regurgitation of the aorta valve.
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Human leukocyte antigen (HLA) is a gene complex on the 
6th chromosome which has several classes including the 
HLA-B27. HLA-B27 has a major role in susceptibility of a 
person to a number of autoimmune diseases [1, 2]. The prev-
alence of this gene in the general population in Iran and the 
Middle East has been reported 8% and 3-5%, respectively [3-
5].
The association of HLA with pathogenesis of ankylosing 
spondylitis (AS) is well known. The role of HLA-B27 in the 
pathogenesis of AS and higher cardiovascular mortality in 
this disease have increased the efforts to determine the role of 
this antigen in cardiac diseases. The results of these researches 
have shown that a variety of cardiovascular problems are di-
rectly associated with HLA-B27. Aortic root dilation, aortic 
valve and mitral valve regurgitation, myocarditis, heart fail-
ure, pericarditis, pericardial effusion, atrioventricular (AV) 
node conduction block, and J-wave syndrome are some of 
these diseases [6, 7]. On the other hand, electrophysiologic 
studies showed that conduction disorders in the AV node are 
more prevalent in carriers of HLA-B27 [6].
In the current study we aimed to evaluate the association be-
tween the AV node blocks and the presence of HLA-B27 in 
Iranian patients undergoing permanent pacemaker implan-
tation with regard to lesser prevalence of this antigen in the 
Iranian society compared with European countries and the 
United States population [5].
METHODS
This cross-sectional prospective study was approved by Qa-
zvin University of Medical Sciences Ethical Committee and 
was conducted by the Cardiology Department of Booali-Si-
na Hospital, Qazvin, from January 2014 to January 2015. All 
the patients who were candidates for permanent pacemaker 
implantation according to American College of Cardiology/
American Heart Association (ACC-AHA) guidelines were 
enrolled in this study. Patients with iatrogenic atrioventric-
ular blocks such as post-electrophysiological study and cath-
eter ablation or post-cardiac surgery were excluded. Patients 
who were on AV nodal blocking agents were included in this 
study if the AV conductions were impaired after discontinua-
tion of the drug for at least five half-lives.
All the patients were informed about the study protocol and 
then provided a written informed consent. Venous blood 
sample was used for the detection of HLA-B27 antigen in all 
the included patients. Patients were divided into two groups 
according to presence of HLA-B27.
Data were analyzed using SPSS 16.0 for Windows (SPSS Inc. 
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Chicago, IL, USA) and were presented as numbers (frequen-
cy). Chi-squared test, Fisher’s exact and Mann-Whitney U 
were used to analyze the qualitative variables between the 
two groups. P < 0.05 was considered as the significance level 
between the treatments.
RESULTS
In this study 103 patients were evaluated. Demographic fea-
tures are shown in Table 1.
Complete heart block was observed in 72 patients 
(69.9%); 9 (8.7%) patients had second-degree AV block 
and 4 (6.8%) had sick sinus syndrome. Simultaneous in-
volvement of AV node and SA node was seen in four pa-
tients. Other kinds of AV block including prolonged HV 
interval were the indications of pacemaker implantation 
in 11 patients.
There was no significant difference in the indications of pace-
maker implantation between male and female patients.
HLA-B27 was positive in only 6 (5.8%) patients. Fifty per-
cent of them had complete heart blocks. Distributions of this 
antigen based on the variety of conduction disturbances are 
shown in Table 2. Although HLA-B27 was more positive in 
male patients, the difference between the two genders was 
not significant.
Aortic valve regurgitation was more prevalent in patients 
with positive HLA-B27 compared with the negative group 
(5 (83.3%) vs. 39 (40.2%) respectively, P = 0.05).
Table 1: Baseline Characteristics of the Patients a, b
Results
 Age 14.32 ± 7.01
Sex, Male 54 (52.4)
 Smoker 20 (19.4)
Diabetes 28 (27.2)
Hypertensive 69 (67)
Ischemic Heart Disease 66 (64.1)
Normal/Mild CAD 29 (28.1)
Single Vessel Disease 20 (19.4)
Two Vessel Disease 3 (2.9)
Three Vessel Disease 14 (13.6)
Unknown 37 (35.9)




ASD Closure 1 (1)
Arotic Valve Involvment 42 (42.7)
Mild 36 (34.9)
Moderate-Severe 8 (7.8)
a Data in table are presented as No. (%) or Mean ± SD.
 b Abbreviations: CAD, coronary artery disease; MVR, mitral valve replacement; AVR, aortic valve replacement; ASD, atrial septum defect;
CABG, coronary artery bypass graft.
Table 2: Prevalance of Conduction Disterbance (P = 0.180) a, b
CHB  Second-Degree AV Block SSS AV Block + SSS Others *
HLA-B27 Negtive (n = 97) 69 (71.1) 9 (9.3) 5 (5.2) 4 (4.1) 10 (10.3)
HLA-B27 Positive (n = 6) 3 (50) 0 (0) 2 (33.3) 0 (0) 1 (16.7)
a Data in table are presented as No. (%) or Mean ± SD.
b Abbreviations: CHB, complete heart block; AV, atrioventricular; SSS, sick sinus syndrome.
* Includeing prolonged HV interval.
Table 3: Prevalance of Aortic Valve Involvement According to HLA-B27 (P = 0.05) a
No Arotic Valve Regurgitation Arotic Valve Regurgitation
HLA-B27 Negtive (n = 97) 58 (59.8) 39 (40.2)
HLA-B27 Positive (n = 6) 1 (16.7) 5 (83.3)
a Data in table are presented as No. (%) or Mean ± SD.
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DISCUSSION
Previous studies showed that HLA-B27 was positive in 
15-20% of Patients who had pacemakers (8). In our study, 
positive HLA-B27 test was less frequent and was only seen 
in 6 (5.8%) patients. The prevalence of HLA-B27 positiv-
ity is lower in the Iranian population compared to many 
other countries, and this may explain the lower frequency 
of HLA-B27 in our study. In a previous study, Adib et al. 
found that the prevalence of HLA-B27 in the healthy Irani-
an population was about 8.6% [4]. The overall frequency of 
HLA-B27 in the Iranian society has been reported to be 2.5 
to 8.6% [3-5].
About 2-10% of patients with AS have some kind of heart 
involvement. On the other hand, it has been approved that 
patients with AS have not only aortic involvement, but also 
increased risk of conduction defects, valvular diseases and 
cardiomyopathy [8].
Increased prevalence of cardiac pacemaker implantation in 
young males with AS and other rheumatologic diseases asso-
ciated with HLA-B27 theorized that perhaps the HLA-B27 
alone and not in the form of rheumatic disease is associated 
with conduction disorders. Expression of HLA-B27 in patients 
with AS may be responsible for cardiac involvement [9, 10]. 
Bergfeldt et al. evaluated that cardiac conduction disorders 
might be associated with HLA-B27 alone or not [11]. Berg-
feldt et al. found out that permanent pacemaker implantation 
had a higher prevalence in patients with positive HLA-B27 
compared with seronegative arthritis patients. They showed 
that significantly more complete heart block occurs as the in-
dication of pacemaker implantation in patients with HLA-B27 
[11]. In our study as well as Bergfeldt’s study, complete heart 
block was higher as the indication of pacemaker, although this 
finding was not significant in our study.
Brags-Armas and his colleagues observed that 5% of patients 
undergoing cardiac pacemaker had HLA-B27; however, in 
their study, positive HLA-B27 was not much prevalent in pa-
tients with permanent pacemakers compared with a control 
group without pacemaker [12].
In a study published in 1983, Bergfeldt et al. stated that the 
pathophysiology of AV block may be the same as AS. In an 
electrophysiological study of 12 patients with HLA-B27-as-
sociated diseases and complete heart block, they found that 
these patients had predominantly suprahisian location of 
AV block and also their conductive systems were diffusedly 
affected. They suggested that HLA-B27 was one of the causes 
of high-grade AV block [8]. In our study, three out of six pa-
tients had AV block and one had fascicular block. However, 
in our study, no significant difference was observed between 
types of conduction disturbances.
Bergfeldt found that the frequency of HLA-B27 was high-
er in pacemaker-treated males in contrast with females and 
suggested a gender-linked difference in disease susceptibility 
[13]. The positivity of HLA-B27 was not significantly differ-
ent in both genders in our study which may be due to our 
small sample size.
There have been two prevalent theories about the etiology of 
conduction disturbances in patients with AS: inflammation 
in the intraventricular septum, leading to damage and anom-
alies in the AV nodal artery, leading to AV node dysfunction. 
The pathophysiological explanation for the role of HLA-B27 
and conduction disturbances is not completely understood. 
Anomalies in the AV nodal artery or AV node damage due 
to inflammation of intraventricular septum may be associated 
with AV nodal conduction disturbance in patients with posi-




There is no conflict of interest.
FUNDING
Authors declared there is no funding or support.
REFERENCES
1. Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s 
heart disease : a textbook of cardiovascular medicine. 10th ed2015.
2. Garcia-Medel N, Sanz-Bravo A, Alvarez-Navarro C, Gomez-Molina 
P, Barnea E, Marcilla M, et al. Peptide handling by HLA-B27 sub-
types influences their biological behavior, association with ankylos-
ing spondylitis and susceptibility to endoplasmic reticulum amino-
peptidase 1 (ERAP1). Mol Cell Proteomics. 2014;13(12):3367-80. 
DOI: 10.1074/mcp.M114.039214 PMID: 25187574
3. Alavi SM, Seraj MS, Etemadi A, Moradzadegan H. Frequency of 
HLA-B27 antigen in Iranian patients with brucellosis and it’s rela-
tionship with osteoarticular complication. Pak J Med Sci April-June. 
2009;25(2):253-6. 
4. Adib KM, Hosseini H. Association of HLA_B27 with anky-
losing spondylitis in Isfahan, Iran. Med J Islamic Repub Iran. 
1994;8(3):159-61. 
5. Khan MA. HLA-B27 and its pathogenic role. J Clin Rheumatol. 
2008;14(1):50-2. DOI: 10.1097/RHU.0b013e3181637a38 PMID: 
18431102
6. Vinsonneau U, Brondex A, Mansourati J, Saraux A, Cornily JC, 
Arles F, et al. Cardiovascular disease in patients with spondyloar-
thropathies. Joint Bone Spine. 2008;75(1):18-21. DOI: 10.1016/j.
jbspin.2007.04.011 PMID: 17913549
7. Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predis-
posing factors in spondyloarthropathies. Curr Opin Rheumatol. 
2001;13(4):265-72. PMID: 11555726
8. Bergfeldt L, Vallin H, Edhag O. Complete heart block in HLA B27 
associated disease. Electrophysiological and clinical characteristics. 
Br Heart J. 1984;51(2):184-8. DOI: 10.1136/hrt.51.2.184 PMID: 
6607060
9. Bergfeldt L. HLA B27-associated rheumatic diseases with severe car-
diac bradyarrhythmias. Clinical features and prevalence in 223 men 
with permanent pacemakers. Am J Med. 1983;75(2):210-5. DOI: 
10.1016/0002-9343(83)91193-2 PMID: 6603791
10. Moyssakis I, Gialafos E, Vassiliou VA, Boki K, Votteas V, Sfikakis PP, et 
al. Myocardial performance and aortic elasticity are impaired in patients 
with ankylosing spondylitis. Scand J Rheumatol. 2009;38(3):216-21. 
DOI: 10.1080/03009740802474672 PMID: 19229673
11. Bergfeldt L, Moller E. Complete heart block--another HLA B27 
associated disease manifestation. Tissue Antigens. 1983;21(5):385-
90. DOI: 10.1111/j.1399-0039.1983.tb00188.x PMID: 6868058
12. Bruges-Armas J, Lima C, Simas Lopes D, Schneider V, Paisana Lopes 
JP, Ferreira Gomes A, et al. HLA-B27 in patients with a permanent 
pacemaker. Ann Rheum Dis. 2003;62(10):1018. DOI: 10.1136/
ard.62.10.1018 PMID: 12972488
13. Bergfeldt L, Moller E. Pacemaker treated women with heart block 
have no increase in the frequency of HLA-B27 and associated rheu-
matic disorders in contrast to men--a sex linked difference in disease 
susceptibility. J Rheumatol. 1986;13(5):941-3. PMID: 3493346
14. Momeni M, Taylor N, Tehrani M. Cardiopulmonary manifesta-
tions of ankylosing spondylitis. Int J Rheumatol. 2011;2011. DOI: 
10.1155/2011/728471 PMID: 21547038
